The use of recombinant FVIIa in a patient with glanzmann thrombasthenia with uncontrolled bleeding after tonsillectomy

Erduran E., Aksoy A., Zaman D.

Blood Coagulation and Fibrinolysis, vol.20, no.3, pp.215-217, 2009 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 20 Issue: 3
  • Publication Date: 2009
  • Doi Number: 10.1097/mbc.0b013e32831d0f69
  • Journal Name: Blood Coagulation and Fibrinolysis
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.215-217
  • Keywords: Glanzmann thrombasthenia, recombinant FVIIa, tonsillectomy
  • Ondokuz Mayıs University Affiliated: No

Abstract

Glanzmann's thrombasthenia is an inherited platelet function disorder caused by quantitative or qualitative defects of the platelet membrane glycoprotein IIb/IIIa complex. Activated recombinant factor VII (rFVIIa) has recently been used in the treatment of patients with Glanzmann's thrombasthenia. We report herein a 16-year-old boy with Glanzmann's thrombasthenia who did not respond to conservative treatment for excessive bleeding and hyperfibrinolysis after tonsillectomy and who was successfully treated with rFVIIa. We suggest that rFVIIa at repeated doses of 80-100 μg/kg may be used effectively in patients with Glanzmann's thrombasthenia having excessive bleeding associated with hyperfibrinolysis after tonsillectomy in addition to tranexamic acid treatment. © 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.